YOLFTbeta
Biohaven Ltd.

Biohaven Ltd.

BHVN · NYSE · Healthcare / Biotechnology

13.82USD-0.25 (-1.78%)

Price History

Full chart

Market Stats

Previous Close14.07
Open14.29
Day Range13.37 – 14.29
52-Week Range7.48 – 18.24
Volume1.25M
Market Cap2.30B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.77
Dividend Yield0.00%
Beta3.13
50-Day Avg13.61
200-Day Avg12.28

About

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Vladimir Coric M.D.
  • Employees274
  • Headquarters215 Church Street, New Haven, CT, United States, 06510, USA
  • Websitehttps://www.biohaven.com

Leadership

  • Dr. Vladimir Coric M.D.Chairman & CEO · b. 1971
  • Mr. Matthew ButenChief Financial Officer · b. 1961
  • Ms. Kimberly GentileSenior Vice President of Clinical Operations · b. 1966
  • Dr. Bruce D. Car D.V.M., DACVP, Ph.D.Chief Innovation Officer · b. 1962
  • Ms. Deb YoungSenior Director of Regulatory Affairs & Operations
  • Mr. George C. Clark CPAVP & Chief Accounting Officer · b. 1985
  • Mr. John McGillChief Technology Officer
  • Ms. Jennifer PorcelliVice President of Investor Relations
  • Mr. Warren Volles J.D.General Counsel & Chief Legal Officer
  • Mr. Clifford Bechtold M.S.President & GM of Biohaven Ireland Chief Compliance Officer

Financials

Income Statement

Currency: USD2017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0462.51M0000
Growth (%)-----100.00%---
Cost of Revenue--72.00K1.39M1.39M3.37M3.92M4.14M
Gross Profit---72.00K370.85M-1.39M-3.37M-3.92M-4.14M
Gross Margin---80.18%----
Operating Expense--114.43M589.75M566.55M432.68M881.19M741.24M
Operating Income--479.12M-114.51M-218.90M-567.93M-436.05M-885.11M-745.38M
Operating Margin----47.33%----
EBITDA--479.12M-114.43M-211.04M-568.46M-402.64M-837.83M-727.46M
EBITDA Margin----45.63%----
Net Income--528.80M-118.67M-213.80M-570.28M-408.17M-846.42M-738.82M
Net Income Margin----46.23%----
R&D-344.67M98.46M181.49M437.07M373.28M795.87M635.07M
R&D as % of Total Revenue---39.24%----
Interest Expense-12.71M-41.55M1.39M---
Interest Expense % of Total Revenue---8.98%----

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets146.89M290.01M344.26M111.50M142.06M661.78M513.21M615.11M451.45M
Total Liabilities14.92M139.09M351.69M34.72M47.37M123.01M85.24M191.67M399.38M
Total Equity131.97M150.92M-7.42M76.78M94.69M538.77M427.98M423.44M52.07M
Cash131.47M264.25M316.73M82.51M76.06M204.88M248.40M99.13M229.96M
Total Debt-117.52M-267.46M627.16M33.60M30.88M36.58M284.61M
Net Debt-131.47M-146.73M-316.73M184.95M550.66M-171.28M-217.53M-62.55M54.66M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-94.81M-197.14M-377.33M-75.96M-145.84M-297.69M-331.73M-582.45M-609.44M
Investing Cash Flow-7.04M-10.54M-3.78M-2.70M944.00K-304.79M129.83M-244.97M300.56M
Financing Cash Flow209.76M340.46M434.59M152.24M138.45M767.60M211.91M677.77M439.12M
Capital Expenditure541.00K4.17M2.53M2.70M938.00K41.07M3.05M4.05M715.00K
Free Cash Flow-95.36M-201.31M-379.87M-78.65M-146.78M-338.76M-334.77M-586.50M-610.15M
FCF to OCF100.57%102.11%100.67%103.55%100.64%113.80%100.92%100.70%100.12%

Earnings

Report DateJan 2, 1991Mar 1, 2017Jun 15, 2017Aug 14, 2017Nov 14, 2017Mar 6, 2018May 15, 2018Aug 14, 2018Nov 13, 2018Feb 28, 2019May 7, 2019Aug 8, 2019Nov 1, 2019Feb 25, 2020May 7, 2020Aug 10, 2020Nov 9, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Feb 25, 2022May 10, 2022Aug 5, 2022Nov 9, 2022Mar 23, 2023May 12, 2023Jul 31, 2023Nov 14, 2023Feb 29, 2024May 9, 2024Aug 8, 2024Nov 12, 2024Mar 3, 2025May 12, 2025Aug 11, 2025Nov 10, 2025Mar 19, 2026May 4, 2026Aug 10, 2026Oct 29, 2026Nov 9, 2026
EPS Estimate0.000.00-0.79-0.61-1.10-1.20-1.14-1.18-1.07-1.21-1.48-1.92-1.57-1.87-2.34-2.61-2.89-2.97-2.82-2.72-2.40-2.04-2.53-2.58-2.41-1.22-1.41-1.19-1.34-1.41-1.62-1.70-1.55-1.60-1.47-1.57-1.54-1.18-0.76-0.77-0.80-0.80
EPS Actual-4.670.00-1.74-1.78-1.19-0.75-2.32-1.01-1.53-1.34-1.41-4.67-2.04-2.85-3.07-3.08-3.27-3.62-4.21-3.23-2.63-3.01-2.97-6.21-1.75-3.32-1.03-1.32-1.50-1.81-1.77-3.50-1.74-1.71-1.64-1.63-1.47-0.90-0.69-0.91-0.86-
Surprise---120.25%-191.80%-8.18%37.50%-103.51%14.41%-42.99%-10.74%4.73%-143.23%-29.94%-52.41%-31.20%-18.01%-13.15%-21.89%-49.29%-18.75%-9.58%-47.55%-17.39%-140.70%27.39%-172.13%26.95%-10.92%-11.94%-28.37%-9.26%-105.88%-12.26%-6.88%-11.56%-3.82%4.55%23.73%9.21%-18.18%-7.50%-
Timing--After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursPre-marketPre-market-After-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap2.30B
Enterprise Value2.33B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book203.79
EPS-3.77
Book Value-0.65
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-478.05M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-799.46%
Return on Assets-90.57%
Shares Outstanding151.06M
Shares Float116.59M
Beta3.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 17 analystsTarget 23.73
  • Strong Buy
    9
  • Buy
    3
  • Hold
    4
  • Sell
    1

Ownership Breakdown

Institutions
95.95%
Insiders
11.20%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    13.21M8.75%
  • Suvretta Capital Management, LLC
    10.29M6.81%
  • Stifel Financial Corp
    9.94M6.58%
  • Jupiter Topco LLC
    8.58M5.68%
  • Woodline Partners LP
    7.66M5.07%
  • State Street Corp
    6.95M4.60%
  • D. E. Shaw & Co LP
    4.19M2.77%
  • AQR Capital Management LLC
    4.15M2.75%
  • Geode Capital Management, LLC
    3.32M2.20%
  • FMR Inc
    2.96M1.96%
  • Royalty Pharma Sub-Manager, LLC
    2.94M1.94%
  • Cormorant Asset Management, LLC
    2.61M1.73%
  • The Goldman Sachs Group Inc
    2.58M1.71%
  • UBS Group AG
    2.52M1.67%
  • Vanguard Portfolio Management, LLC
    2.49M1.65%
  • Balyasny Asset Management LLC
    1.88M1.24%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    3.97M2.63%
  • iShares Russell 2000 ETF
    3.39M2.24%
  • Fidelity Select Biotechnology
    2.18M1.44%
  • HBM Healthcare Investments AG Ord
    1.94M1.28%